Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 23, 2026

Back to today

From X

@convequity

Convequity on X

We think $MNDY needs to make its platform verifiable to lead work management. MNDY has not disclosed its AI ARR in dollars. Our recent SaaS Survival Scorecard report estimates it at about $20 to $30 million as of the end of Q2 2026. Leading AI-native startups in other fields are far larger. In coding, Cognition reported crossing $1 billion in annualized revenue run rate on 25 September 2026, company-wide across Devin and Windsurf. In legal work, Harvey reported on 1 October 2026 that it crossed $400 million in ARR during Q3 2026. We think MNDY has long been highly adaptive, with great leadership and a strong recent cadence of features and products. But revenue growth has slowed, and in our view it has gained little from AI so far, because work management is a hard area for AI. In our view, coding agents suddenly became highly effective around early 2026, and work management has not yet had its own coding moment. Verifiability is the key difference: code can be tested, while most work management outcomes are hard to check. Rather than wait for that moment, how can MNDY make work management more verifiable? It could track and measure the actions taken on its platform and their outcomes, so that everything that happens there is verifiable. MNDY can learn from Palantir. Palantir launched AIP in 2023, its AI platform built on its ontology, and we think that ontology helped Palantir succeed with models much weaker than today's. Could MNDY build a similar substrate or ontology for work management in order to make the work done on its platform more verifiable? We do not claim to have the answer. Our view is that to thrive, and not only survive, MNDY needs to lead work management by making its platform verifiable, however it chooses to do that.

Investor Letters

All letters

Capital Wars

CoreWeave’s $35 billion to $39 billion 2026 spending plan relies on debt as unsecured yields reach 15%, making its GPU cloud expansion a…

CRWV $34B
Net Interest 8 clicks

Putting bear cases to rest

Medpace authorized $1 billion of buybacks through 2028 after Q3 revenue rose 8.5% to $716 million; service revenue grew roughly 12% as…

MEDP $18B
Best Anchor Stocks 11 clicks
PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

PYPD $103M
Value Investors Club

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 56 of 248

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.